To recover your password please fill in your email address
Please fill in below form to create an account with us
An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
See ANZCTR for full trial details >
|
Trial Summary: |
ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Prognostic and predictive factors will be studied from tumour and blood samples. |
|
Supported By: |
Cancer Australia, UCL Cancer Trials Centre, Astra Zeneca |
|
Eligibility: |
Histologically proven diagnosis of high grade serous or endometrioid carcinoma of the ovary, fallopian tube or peritoneum, progressing more than 6 months after day 1 of the last cycle of first-line platinum-based chemotherapy and requiring treatment with second-line platinum-based chemotherapy |
|
Registration ID: |
NCT03278717 |
|
Participation: |
Australia, UK |
|
Australian Lead Group: |
ANZGOG |
|
Status: |
In follow up |
|
Activation Date: |
12.11.2018 |
|
Chairs: |
A/Prof Linda Mileshkin |
|
Contact: |